News | Endovascular Aortic Repair | October 08, 2018

FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

Safety notice was related to increased occurrence of Type III endoleaks after endovascular aneurysm repair (EVAR)

FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

October 8, 2018 — Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall action that Endologix took in July of this year as a Class I recall. The July recall involved Endologix’s issuance of a Safety Notice to healthcare professionals (HCPs) using the AFX Endovascular AAA System.

The Safety Notice, dated July 20, 2018, provided updated information on comparative AFX Type III endoleak rates, patient-tailored surveillance recommendations, and recommendations for intervening through an AFX device or re-intervening on an AFX device. No product was removed from the field as part of this recall.

The July 2018 Safety Notice followed several earlier communications. Safety Notices from Endologix issued in late 2016 and early 2017 requested that all remaining AFX Strata devices be returned from the field and emphasized that Endologix had not manufactured AFX Strata grafts since 2014. On Sept. 28, 2017, the FDA issued a letter to HCPs to raise awareness of an increased occurrence of Type III endoleaks after endovascular aneurysm repair (EVAR). On June 19, 2018, the FDA issued an updated letter to HCPs indicating the increased risk for Type III endoleak appears to be specific to one device at this time, the AFX with Strata device. 

“As outlined at our Investor Day on Oct. 2, 2018, the AFX Strata product was removed from global inventory in the first half of 2017. Our current commercially available versions of the AFX system, the AFX Duraply and AFX2 products, are manufactured using a different ePTFE processing methodology and include additional product improvements,” noted John Onopchenko, chief executive officer of Endologix. “These AFX Duraply and AFX2 products, while part of the July 2018 Safety Notice providing updated recommendations to HCPs on how to re-intervene on or through these products, were not the subject of the voluntary product removal actions in December 2016/January 2017. Furthermore, AFX Duraply and AFX2 products were not the subject of the June 19, 2018 FDA letter to HCPs. Through our comprehensive system of post-market surveillance, anonymized registry data, and the only randomized trial to compare EVAR systems (the LEOPARD trial), we have a strong and growing evidence base that supports the use of the AFX Duraply and AFX2 systems for patients with AAA. We are proud of, and committed to, advancing our collaborative work with the FDA on behalf of our patients, customers, and the broader clinical community.”

For more information: www.endologix.com

Related Content

Obese Patients Have More Post-Op Problems Following AAA Repair
News | Endovascular Aortic Repair | November 21, 2018
New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...
Beaumont Hospital, Michigan, endovascular aortic repair, EVAR, conscious sedation
News | Endovascular Aortic Repair | July 08, 2016
Kirk Schoenherr, 56, of Clinton Township, Mich., recently became just the second patient at Beaumont Hospital, Royal...
Aptus Endosystems, Medtronic, acquisition, Heli-FX, Thoracic EndoAnchor, EVAR

Heli-FX image courtesy of Aptus Endosystems

News | Endovascular Aortic Repair | July 02, 2015
Medtronic plc announced it has acquired the assets of Aptus Endosystems Inc., a privately held medical device company...
Overlay Init